In May of 2021, the FDA-approved sotorasib, a RAS GTPase inhibitor, for treatment in those with KRAS G12C mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy87. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.